Skip to content
Sulesomab
LeukoScan (sulesomab) is an antibody pharmaceutical. Sulesomab was first approved as Leukoscan on 1997-02-14. It has been approved in Europe to treat osteomyelitis and radionuclide imaging.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
diagnosisD003933
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09H: Inflammation and infection detection
— V09HA: Technetium (99mtc) compounds
— V09HA04: Technetium (99mtc) sulesomab
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EndocarditisD004696EFO_0000465I33———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic footD017719EFO_1001459————11
OsteoarthritisD010003EFO_0002506M15-M19————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSULESOMAB
INNsulesomab
Description
Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells. Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID167747-19-5
RxCUI—
ChEMBL IDCHEMBL2108809
ChEBI ID—
PubChem CID—
DrugBankDB13976
UNII ID709B6VM65P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 105 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details